Abstracts tagged "quality of care"

Abstract Number: 1089 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic
Nagendra Pokala¹, Benjamin Gardner², Avni Amratia¹, Daniel Emesiani³, Jiby Mathew⁴, Rashmi Arora⁵, Una Makris⁶ and Swathi Reddy⁷, ¹Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, ³Baylor Scott and White Medical Center McKinney, Dallas, TX, ⁴VA North Texas Healthcare System, Dallas, TX, ⁵Department of Internal Medicine, UT Southwestern Medical Center; VA North Texas Healthcare System, Dallas, TX, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁷UT Southwestern Medical Center / Dallas VA Medical Center, Colleyville, TX
Background/Purpose: Due in part to immunosuppressant medications, patients with rheumatic diseases not only carry a higher risk of herpes zoster reactivation but also worse outcomes.…
Abstract Number: 1899 • ACR Convergence 2023
Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States
Jinoos Yazdany¹, April Jorge², Claire Barber³, April Barnado⁴, Bonnie Bermas⁵, Ali Duarte-Garcia⁶, Amy Bennett⁷, Candace Feldman⁸, Shivani Garg⁹, Leah Haseley¹⁰, Shraddha Jatwani¹¹, Tracy Johansson¹², Alex Limanni¹³, Wambui Machua¹⁴, Wendy Rodgers¹⁵, Brad Rovin¹⁶, Yesenia Santiago-Casas¹⁷, Lisa Suter¹⁸, JoAnn Zell¹⁹, Patti Katz²⁰ and Christie M. Bartels²¹, ¹University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ²Massachusetts General Hospital, Boston, MA, ³University of Calgary, Calgary, AB, Canada, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵UT Southwestern, Dallas, TX, ⁶Mayo Clinic, Rochester, MN, ⁷ACR, Atlanta, GA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹⁰University of Washington, Seattle, WA, ¹¹Dignity Health-MMG Rheumatology, East Norriton, PA, ¹²American College of Rheumatology, Atlanta, GA, ¹³Self, Dallas, TX, ¹⁴Piedmont Healthcare, Atlanta, GA, ¹⁵Lupus Foundation of America, Los Angeles, CA, ¹⁶Ohio State University, Columbus, OH, ¹⁷Guillermo Valenzuela MD PA, Plantation, FL, ¹⁸Yale School of Medicine, New Haven, CT, ¹⁹University of Colorado Anschutz Medical Campus, Denver, CO, ²⁰University of California San Francisco, San Rafael, CA, ²¹University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Collaborating with the Centers for Disease Control and Prevention (CDC), the ACR has developed new quality measures for lupus clinical care, including clinical and…
Abstract Number: 2484 • ACR Convergence 2023
Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management
Ruchi Patel¹, Kristen Salava¹, Eric Newman², Joseph Chronowski¹, Dante Grassi¹, Hillary Harris³, Amanda Young¹, Idorenyin Udoeyo², Lisa Schroeder², David Bulbin⁴, David Pugliese⁵ and Jonida Cote⁶, ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA, ³Geisinger, Wilkes Barre, PA, ⁴Geisinger Health System, Danville, PA, ⁵Geisinger Health System, Wilkes-Barre, PA, ⁶Geisinger Medical Center, Orefield, PA
Background/Purpose: More effective teamwork can improve patient care. We studied the effect of a Rheumatologist-Pharmacist Co-management program on the quality of care of rheumatology patients…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 1091 • ACR Convergence 2023
Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
Raphael Kirou, Cesar Avalos and Ellen Ginzler, SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: Quality of care (QoC) in SLE patients has been studied by Schmajuk et al. (Arthritis Care Res2022), who developed six quality measures assessing blood…
Abstract Number: 1900 • ACR Convergence 2023
Assessment of Hospitalist Confidence Levels in Management of Rheumatic Conditions to Identify Potential Knowledge Gaps
Lily Sung, Amber Young and Jiha Lee, University of Michigan, Ann Arbor, MI
Background/Purpose: Healthcare utilization, including hospitalization, is high among patients with rheumatic musculoskeletal diseases (RMD). As the primary care providers during admission, hospitalists play a key…
Abstract Number: 2556 • ACR Convergence 2023
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
Jiacai Cho¹, Liang Shen², Rangi Kandane-Rathnayake³, Vera Golder³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian J Wu⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹⁴, BMDB Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Shereen Oon²⁰, Sean O’Neill²¹, Fiona Goldblatt²², Kristine Ng²³, Annie Law²⁴, Nicola Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra⁹, Chak Sing Lau²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹, Eric Morand³² and Aisha Lateef³³, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Peking University People’s Hospital, Beijing, China, ¹¹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ¹⁶Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁷Keio University, Keio, Japan, ¹⁸Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²⁰Department of Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²¹Department of Medicine, University of New South Wales, Kensington, Australia, ²²Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²³Waitemata DHB, Auckland, New Zealand, ²⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²⁵Auckland District Health Board, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Manila, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ³²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³³National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore
Background/Purpose: SLE patients suffer high symptom burden at the end-of-life. However, the course of disease and treatment burden in the last year of life have…
Abstract Number: 0752 • ACR Convergence 2023
Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA
Background/Purpose: Screening for latent tuberculosis (TB) is recommended prior to starting biologics or targeted synthetic DMARDs (b/tsDMARDs). With a growing number of these drugs available…
Abstract Number: 1092 • ACR Convergence 2023
Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Lilian Otalora Rojas¹, Gurjit S Kaeley² and Myint Thway³, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL, ³UF Jacksonville, Ponte Vedra, FL
Background/Purpose: Nephritis remains one of the most devastating complications of Systemic lupus erythematosus (SLE). Lupus nephritis (LN) significantly reduces overall survival to approximately 88% at…
Abstract Number: 1904 • ACR Convergence 2023
Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs
Douglas White¹, Maya Buch², Suzanne Murray³, Diane Caballero⁴, Orsolya Nagy⁵ and Tsutomu Takeuchi⁶, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ³AXDEV Group Inc, Brossard, QC, Canada, ⁴AbbVie, Inc., Chicago, IL, ⁵AbbVie, Inc., Budapest, Hungary, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Treat-to-target (T2T) is a widely established and accepted approach in RA management, but its real-world implementation is suboptimal1. Further primary research is required to…
Abstract Number: 0753 • ACR Convergence 2023
Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System
Jeremy Sullivan¹, Anna Ware², Gary Tarasovsky³, Cherish Wilson⁴, Mary Whooley³, Jasvinder Singh⁵, Jinoos Yazdany⁶ and Gabriela Schmajuk⁴, ¹University of California San Francisco, San Francisco, CA, ²Palo Alto VA, Minneapolis, MN, ³San Francisco VA, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…
Abstract Number: 1095 • ACR Convergence 2023
Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures
Emma Kersey¹, Jing Li¹, Julia Kay¹, Julia Adler-Milstein¹, Jinoos Yazdany² and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: The American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) EHR-based registry facilitates quality measure calculation and reporting for rheumatology practices in national…
Abstract Number: 1905 • ACR Convergence 2023
Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic
Rumey Ishizawar¹, Thuyvan Phan² and Steven Takacs³, ¹University of North Carolina at Chapel Hill, School of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina Hospitals Department of Pharmacy, Apex, NC, ³University of North Carolina Faculty Physicians, Chapel Hill, NC
Background/Purpose: The 2021 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) recommend a treat-to-target approach to optimize clinical outcomes. This…
Abstract Number: 0755 • ACR Convergence 2023
Changes in Rheumatology Providers’ Perceptions of Telehealth Appropriateness from 2021 to 2022
David Leverenz¹, Mary Solomon², Ricardo Henao², Isaac Smith³, Catherine Howe⁴, Nicoleta Economou-Zavlanos⁵, Bhargav Adagarla⁶, Theresa Coles⁷, AJ Overton⁸, Jayanth Doss⁹ and Megan Clowse¹⁰, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Department of Biostatistics, Durham, NC, ³Duke University, Department of Medicine-Rheumatology and Immunology, Durham, NC, ⁴New York University, New York, NY, ⁵Duke AI Health, Durham, NC, ⁶Duke University Clinical Research Institute, Durham, NC, ⁷Duke University, Department of Population Health Sciences, Durham, NC, ⁸Consultant, Durham, NC, ⁹Duke University, Durham, NC, ¹⁰Duke University, Chapel Hill, NC
Background/Purpose: Telehealth in rheumatology rapidly expanded in the wake of the COVID-19 pandemic, however it remains unknown how provider perceptions of telehealth changed as the…
Abstract Number: 1096 • ACR Convergence 2023
A Quality Improvement Project About Medication Adherence to Understand What Questions Rheumatology Patients Have About Their Medications, and How They Answer Them
Lena Eder¹, Kai Sun², Sonali Bracken³, Ann Cameron Barr⁴, Jeffrey Shen⁴, Dahima Cintron⁴, Mithu Maheswaranathan⁴, Catherine Sims², Poorva Apte⁴, Megan Milne⁵, Nathaniel Harris⁴ and David Leverenz⁶, ¹Duke University, Chapel Hill, NC, ²Duke University, Durham, NC, ³Duke University Hospital, Apex, NC, ⁴Duke University Hospital, Durham, NC, ⁵Costal Carolina Health Care, New Bern, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Medication non-adherence remains high among rheumatology patients, yet little is known about adherence barriers faced by patients or interventions that improve adherence. As part…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].